• NuWays assigned Eckert & Ziegler a Buy rating with a 12-month price target of EUR 21.50 in its November 13 report.
• Third-quarter adjusted EBIT rose 25% to EUR 19.3 million, driven by a favorable Medical business mix and improving industrial profitability.
• Sales increased 6% to EUR 79.6 million; the adjusted EBIT margin expanded 3.8 percentage points to 24.2%.
• Confirmed fiscal 2026 guidance targets approximately EUR 320 million in sales and EUR 80 million in adjusted EBIT.
• The analyst viewed valuation at approximately eight times estimated enterprise value to EBITDA as modest relative to radiopharmaceutical growth opportunities.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eckert & Ziegler SE published the original content used to generate this news brief via EQS News (Ref. ID: rc_27478) on November 13, 2026, and is solely responsible for the information contained therein.